Briacell Therap (BCTX) News Today $8.00 -0.13 (-1.60%) Closing price 09/12/2025 03:57 PM EasternExtended Trading$7.99 -0.01 (-0.12%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period BriaCell’s Bria-OTS mechanism of action study published by JCI InsightAugust 26, 2025 | msn.comBriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer JournalAugust 26, 2025 | globenewswire.comBriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate CancerAugust 25, 2025 | globenewswire.comBriaCell to effect 1-for-10 share consolidation on August 25August 22, 2025 | msn.comBriaCell Announces Proposed Effective Date of Share ConsolidationAugust 21, 2025 | globenewswire.comBriaCell selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+August 14, 2025 | msn.comBriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for CancerAugust 13, 2025 | globenewswire.comBriaCell Announces Proposed Effective Date of Share ConsolidationAugust 5, 2025 | globenewswire.comBriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer StudyJuly 31, 2025 | globenewswire.comBriaCell Awarded New Zealand Patent for its Whole Cell TechnologyJuly 30, 2025 | globenewswire.comBriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting AgentsJuly 29, 2025 | globenewswire.comBriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025July 25, 2025 | globenewswire.comBriaCell Therapeutics Announces Pricing of $15 million Public OfferingJuly 15, 2025 | globenewswire.comBriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast CancerJuly 15, 2025 | globenewswire.comBriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast CancerJuly 11, 2025 | globenewswire.comBriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer PatientJuly 10, 2025 | globenewswire.comBriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer StudyJuly 9, 2025 | globenewswire.comBriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast CancerJuly 8, 2025 | globenewswire.comBriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New HavenJuly 2, 2025 | globenewswire.comBCTX BriaCell Therapeutics Corp. - Seeking AlphaJune 29, 2025 | seekingalpha.comBriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast CancerJune 24, 2025 | globenewswire.comBriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26June 4, 2025 | globenewswire.comBriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025June 2, 2025 | globenewswire.comBriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint InhibitorMay 27, 2025 | globenewswire.comBriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025May 23, 2025 | globenewswire.comBriaCell Therapeutics Corp.: BriaCell CEO Letter to ShareholdersMay 20, 2025 | finanznachrichten.deBriaCell CEO Letter to ShareholdersMay 20, 2025 | globenewswire.comBriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers IdentifiedApril 30, 2025 | globenewswire.comBriaCell Therapeutics Announces Closing of $13.8 million Public OfferingApril 28, 2025 | globenewswire.comBriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ DevelopmentApril 28, 2025 | globenewswire.comBriaCell 3.07M share Secondary priced at $4.50April 25, 2025 | markets.businessinsider.comBriaCell Therapeutics Announces Pricing of $13.8 million Public OfferingApril 24, 2025 | globenewswire.comBriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™April 24, 2025 | globenewswire.comBriaCell Announces Four Clinical Data Presentations at ASCO 2025April 23, 2025 | globenewswire.comBriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)April 22, 2025 | globenewswire.comBriaCell announces survival data from its Phase 2 study of Bria-IMTApril 17, 2025 | markets.businessinsider.comBriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast CancerApril 16, 2025 | globenewswire.comBriaCell to Present Clinical and Preclinical Data at the 2025 AACR ConferenceMarch 26, 2025 | globenewswire.comSecond Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast CancerMarch 20, 2025 | globenewswire.comBiotechs on the Brink: 2 Stocks With Huge PotentialBriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.February 14, 2025 | marketbeat.comBriaCell Therapeutics Corp. Announces Results of Shareholder MeetingFebruary 5, 2025 | globenewswire.comBriaCell Therapeutics Announces Closing of Public OfferingFebruary 5, 2025 | globenewswire.comH.C. Wainwright raises Briacell stock target to $32 on trial successFebruary 4, 2025 | msn.comBriaCell Therapeutics Announces Pricing of Public OfferingFebruary 3, 2025 | globenewswire.comBriaCell announces public offering of common sharesFebruary 3, 2025 | msn.comBriaCell Therapeutics stock rises on positive clinical trial resultsFebruary 3, 2025 | msn.comBriaCell Therapeutics trading halted, volatility trading pauseFebruary 3, 2025 | markets.businessinsider.comBriaCell Therapeutics Drops 4% Following Metastatic Breast Cancer Trial ResultsFebruary 3, 2025 | markets.businessinsider.comBriaCell Therapeutics Announces Proposed Public Offering of Common SharesFebruary 3, 2025 | globenewswire.comBriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™February 3, 2025 | globenewswire.com Get Briacell Therap News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCTX Media Mentions By Week BCTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCTX News Sentiment▼1.300.92▲Average Medical News Sentiment BCTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCTX Articles This Week▼21▲BCTX Articles Average Week Get the Latest News and Ratings for BCTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Briacell Therap and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SNYR News QTTB News NAII News CTXR News AYTU News LEXX News CING News LIXT News HOTH News LSTA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCTX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Briacell Therap Please log in to your account or sign up in order to add this asset to your watchlist. Share Briacell Therap With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCTX Stock Alerts